Ładuje się......
FDA-Approved Biosimilar Insulin: Good Enough for Critical Care, Adulterated, or Counterfeit? How Can We Tell?
If a biosimilar insulin is discovered postmarketing to be subpotent, superpotent, or contaminated or the contents mislabeled, it is an adulterated product and must be quarantined for removal including from a patient’s home. Adulterated products could be considered “counterfeit” since they do not mee...
Zapisane w:
| Wydane w: | J Diabetes Sci Technol |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
SAGE Publications
2014
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4455370/ https://ncbi.nlm.nih.gov/pubmed/25172881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296814539275 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|